

LIBROS

Canalis E, ed. Skeletal growth factors. Hagerstown: Lippincott Williams & Wilkins, 2000.

NUESTROS AUTORES

Audi L, García Ramires M, Carrascosa A. Genetic determinants of bone mass. *Horm Res* 1999; 51: 105-123.

Moreno A, Torregrosa JV, Pons F, et al. Bone mineral density after renal transplantation: long-term follow-up. *Transplant Proc* 1999; 31: 2.322-2.323.

Talbot JR, Guardo P, Seccia S, et al. Calcium bioavailability and parathyroid hormone acute changes after oral intake of dairy and nondairy products in healthy volunteers. Addition of calcium citrate to powdered milk enhance the inhibitory effect on serum iPTH in the assayed condition. *Osteoporosis Int* 1999; 10: 137-142.

Weisinger JR. Litiasis renal: aspectos fisiopatológicos y afectación del hueso en la hipercalcemia idiopática. *Osteología* 1999; 2: 123-127.

Peris P, Álvarez L, Monegal A, et al. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. *Bone* 1999; 25: 349-353.

García M, Torán N, Andaluz P, et al. Vascular endothelial growth factor is expressed in human fetal growth cartilage. *J Bone Miner Res* 2000; 15: 534-540.

Se ruega a los autores enviar una copia del trabajo para incluir su cita en esta Sección

REVISIONES

Nguyen TV, Blanguero J, Eisman JA. Genetic epidemiological approaches to the search for osteoporosis genes. *J Bone Miner Res* 2000; 15: 392-401.

Falkner KG. Bone matters: Are density increases necessary to reduce fracture risk? *J Bone Miner Res* 2000; 15: 183-187.

Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in celiac disease and inflammatory bowel disease. *British Society of Gastroenterology. Gut* 2000; 46 (Sup 1): 1-8.

Martin RB. Toward a unifying theory of bone remodeling. *Bone* 2000; 26: 1-6.

Parker MJ. Managing an elderly patient with a fractured femur. *Brit Med J* 2000; 320: 102-103.

Strewler GJ. The physiology of parathyroid hormone-related protein. *New Eng J Med* 2000; 342: 177-185.

Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *J Bone Miner Res* 2000; 15: 2-12.

Major PP, Lipton A, Berenson J, et al. Oral bisphosphonates: a review of clinical use in patients with bone metastases. *Cancer* 2000; 88: 6-14.

Hoyland JA, Picton ML. Cellular mechanisms of renal osteodystrophy. *Kidney Intern* 2000; 56: 8-13.

Kanis JA. Vitamin D analogs: from renal bone disease to osteoporosis. *Kidney Intern* 2000; 56: 77-81.

Bland R. Steroid hormone receptor expression and action on bone. *Clin Sci* 2000; 98: 217-240.

Dickinson CJ. The possible role of osteoclastogenic oral bacterial products in etiology of Paget's disease. *Bone* 2000; 26: 101-102.

Todor-Locke C, McColl RS. Factors related to variation in premenopausal bone mineral status: a health promotion approach. *Osteoporosis Int* 2000; 11: 1-24.

Faulkner KG. Bone matters: Are density increases necessary to reduce fracture risk? *J Bone Miner Res* 2000; 15: 183-187.

Subramanian R, Khardori S. Severe hypophosphatemia. Pathophysiologic implications, clinical presentation and treatment. *Medicine* 2000; 79: 1-8.

Tudor-Locke C, McColl RE. Factors related to variation in premenopausal bone mineral status: a health promotion approach. *Calcif Tissue Int* 2000; 65: 1-24.

OTROS ARTÍCULOS DE INTERÉS

Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. *Osteoporosis Int* 2000; 11: 76-82.

Arjmandi BH, Birnbaum RS, Juma S, et al. The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms. *Calcif Tissue Int* 2000; 66: 61-65.

Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. *Brit Med J* 2000; 320: 341-346.

Benichou OD, Laredo JD, de Vernejoul MC. Type II autosomal dominant osteopetrosis: Clinical and radiological manifestations in 42 patients. *Bone* 2000; 26: 87-94.

Dirshl DR, Piedrahita L, Henderson RC. Bone mineral density 6 years after a hip fracture: a prospective, longitudinal study. *Bone* 2000; 26: 95-98.

Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bone metastasis of breast cancer. *Int J Clin Oncology* 1999; 4: 331-337.

Legrand E, Chappard D, Pascaretti C, et al. Trabecular bone microarchitecture, bone mineral density and vertebral fractures in male osteoporosis. *J Bone Miner Res* 2000; 15: 13-19.

Naylor KE, Iqbal P, Fledelius C, et al. The effect of pregnancy on bone density and bone turnover. *J Bone Miner Res* 2000; 15: 129-137.

Roe EB, Chiu KM, Arnaud CD. Selective estrogen receptor modulators and postmenopausal health. *Adv Intern Med* 2000; 45: 259-278.

Daniel HW, Dunn SR, Fergusson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostatic cancer. *J Urol* 2000; 163: 181-186.

- Cueto AM, Konel S, Freemont AJ, et al. Effecto of 1,25-dihydroxyvitamin D an calcium carbonate on bone loss associated with long-term renal transplantation. *Am J Kidney Dis* 2000; 35: 227-236.
- Glorieux FH, Travers R, Taylor A, et al. Normative data for iliac bone histomorphometry in growing children. *Bone* 2000; 26: 103-110.
- Szulc P, Marchand F, Duboeuf F, Delmas PD. Cross-sectional assessment of age-related bone loss in men: the MINOS study. *Bone* 2000; 26: 123-130.
- Nguyen TV, Center JR, Esiman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity and body mass index. *J Bone Miner Res* 2000; 15: 322-331.
- Menaa C, Barsony J, Reddy SV, et al. 1,25-dihydroxyvitamin D, hypersensitivity of osteoclast precursors from patients with Paget's disease. *J Bone Miner Res* 2000; 15: 228-236.
- Diwan AD, Wang MX, Jang D, et al. Nitric oxide modulates fracture healing. *J Bone Miner Res* 2000; 15: 342-351.
- Altman RD, Bloch DA, Hochberg MC, Murphy WA. Prevalence of pelvic Paget's disease of bone in the United States. *J Bone Miner Res* 2000; 15: 461-465.
- Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamina K2 (Menatrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. *J Bone Miner Res* 2000; 15: 515-521.
- Adami S, Braga V, Guidi G, et al. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. *J Bone Miner Res* 2000; 15: 599-604.
- Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. *Calcif Tissue Int* 2000; 65: 83-91.
- Ross PD, Kress BC, Parson RE, et al. Serum bone-alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. *Calcif Tissue Int* 2000; 65: 76-82.
- Ho YV, Frauman AG, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. *Osteoporosis Int* 2000; 11: 98-101.
- Feldkamp J, Becker A, Witte OW, et al. Long-term anticonvulsant therapy leads to low bone mineral density – evidence for direct drug effects on phenytoin and carbamazepine on human osteoblast-like cells. *Exp Clin Endocrinol Diabetes* 2000; 108: 104-110.
- Cameron ID, Stafford D, Cumming RG, et al. Hip protectors improve falls self-efficacy. *Age and Ageing* 2000; 29: 57-62.
- Selby PL, Davies M, Adamas JE. Do men and women fracture bones at similar bone densities? *Osteoporosis Int* 2000; 11: 153-157.
- Leidig G, Limberg B, Felsenberg D, et al. Sex differences in the validity of vertebral deformities as an index of prevalent vertebral osteoporotic fractures: a population survey of older men and women. *Osteoporosis Int* 2000; 11: 102-119.
- Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. *Clin Therap* 2000; 22: 1-14.
- Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. *J Clin Endocrinol Metab* 2000; 85: 231-236.

FE DE ERRATAS

En el artículo publicado dentro de la sección de Informes del número 2 de Revista Española de Enfermedades Metabólicas Óseas, titulado “INFORME PRELIMINAR Y RECOMENDACIONES DE UNA COMISIÓN DE EXPERTOS DE LA ORGANIZACIÓN MUNDIAL DE LA SALUD SOBRE UNA ESTRATEGIA GLOBAL PARA LA OSTEOPOROSIS” (*Rev Esp Enf Metab Oseas* 2000; 9(2): 78-83) aparece un error que pasamos a subsanar.

En la cita bibliográfica que aparece en el primer párrafo de la página 78 se mencionan las páginas 285-293 de un informe publicado por la OMS, cuando, en realidad, las páginas correctas son 259-264.